Wall Street Zen Upgrades Eloxx Pharmaceuticals (NASDAQ:ELOX) to “Hold”

Eloxx Pharmaceuticals (NASDAQ:ELOX) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

A number of other equities analysts also recently issued reports on ELOX. Lifesci Capital began coverage on Eloxx Pharmaceuticals in a research report on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 price objective for the company. Guggenheim started coverage on Eloxx Pharmaceuticals in a report on Monday, July 20th. They issued a “buy” rating and a $43.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $41.50.

Eloxx Pharmaceuticals Stock Performance

Shares of NASDAQ:ELOX opened at $17.43 on Friday. The firm has a market capitalization of $12.03 million, a price-to-earnings ratio of -1.14 and a beta of -1,863.11. The business’s fifty day simple moving average is $16.60. Eloxx Pharmaceuticals has a 52 week low of $13.79 and a 52 week high of $18.42.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.